KAT5 Inhibitor NU9056 Suppresses Anaplastic Thyroid Carcinoma Progression through c-Myc/miR-202 Pathway

Figure 8

Schematic representation of KAT5 inhibitor NU9056 suppresses ATC progression via c-Myc/miR-202 pathway. In ATC cells, elevated KAT5 increases transcription factor c-Myc expression by promoting its protein stabilization. C-Myc then activates miR-202-5p transcription and mediates ATC progression. NU9056 inhibits ATC progression via the blockade of KAT5/c-Myc/miR-202 pathway.